[vc_row type=”standard_section” bg_position=”left top” bg_repeat=”stretch” text_color=”dark” text_align=”center” top_padding=”80″ bottom_padding=”80″][vc_column][minti_headline type=”h2″ align=”align-center” font=”font-special” transform=”transform-inherit” size=”fontsize-m” weight=”fontweight-700″ margin=”0 0 20px 0″ lineheight=”lh-inherit”]Hi-CSCi[/minti_headline][minti_headline type=”div” align=”align-center” font=”font-inherit” size=”fontsize-m” weight=”fontweight-inherit” color=”#999999″ margin=”0″ lineheight=”lh-inherit” transform=”transform-inherit”]A high-throughput screening platform for discovering novel cancer drugs[/minti_headline][vc_column_text]

Key Features

Prostate cancer cell line with reduced Epithelial Protein Lost In Neoplasm (EPLIN) expression.
Cell line exhibits morphology characteristics of malignant cell lines and increased chemoresistance, migration, and invasion.

Technical Summary

Prostate cancer is the second leading cause of cancer-related deaths in males in the United States, and the vast majority of those deaths result from metastatic cancer. We have developed a cell line that could serve as a cell-based model to discover novel drugs targeting lethal prostate cancer cells*.

Developmental Stage

Cell lines have been generated and characterized.

Emory TechID: RT006; Published by Emory University Office of Technology Transfer: May 28, 2013

*Zhang S, Wang X, Osunkoya AO, Chen Z, Iqbal S, Müller S, Chen Z, Josson S, Coleman IM, Nelson PS, Wang R, Shin DM, Marshall FF, Kucuk O, Chung LWK, Zhau HE, Wu D. EPLIN downregulation promotes epithelial-mesenchymal transition in prostate cancer cells and correlates with clinical lymph node metastasis. Oncogene, 30:4941-4952, 2011.